These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24987404)

  • 1. Screening for impaired cognitive domains in a large Parkinson's disease population and its application to the diagnostic procedure for Parkinson's disease dementia.
    Ohta K; Takahashi K; Gotoh J; Yamaguchi K; Seki M; Nihei Y; Iwasawa S; Suzuki N;
    Dement Geriatr Cogn Dis Extra; 2014 May; 4(2):147-59. PubMed ID: 24987404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity.
    Snyder A; Gruber-Baldini AL; Rainer von Coelln F; Savitt JM; Reich SG; Armstrong MJ; Shulman LM
    J Parkinsons Dis; 2021; 11(4):1995-2003. PubMed ID: 34366371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.
    Nazem S; Siderowf AD; Duda JE; Have TT; Colcher A; Horn SS; Moberg PJ; Wilkinson JR; Hurtig HI; Stern MB; Weintraub D
    J Am Geriatr Soc; 2009 Feb; 57(2):304-8. PubMed ID: 19170786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.
    Burdick DJ; Cholerton B; Watson GS; Siderowf A; Trojanowski JQ; Weintraub D; Ritz B; Rhodes SL; Rausch R; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Srivatsal S; Edwards KL; Montine TJ; Zabetian CP; Leverenz JB
    Mov Disord; 2014 Sep; 29(10):1258-64. PubMed ID: 25073717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between the MoCA and the MMSE visuoexecutive sub-tests in detecting abnormalities in TIA/stroke patients.
    Mai LM; Sposato LA; Rothwell PM; Hachinski V; Pendlebury ST
    Int J Stroke; 2016 Jun; 11(4):420-4. PubMed ID: 26865154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
    Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
    Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity and diagnostics of the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson's disease patients.
    D'Iorio A; Aiello EN; Amboni M; Vitale C; Verde F; Silani V; Ticozzi N; Ciammola A; Poletti B; Santangelo G
    Aging Clin Exp Res; 2023 Oct; 35(10):2157-2163. PubMed ID: 37480503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Instrument Combines Cognitive and Social Functioning Items for Detecting Mild Cognitive Impairment and Dementia in Parkinson's Disease.
    Yu YW; Tan CH; Su HC; Chien CY; Sung PS; Lin TY; Lee TL; Yu RL
    Front Aging Neurosci; 2022; 14():913958. PubMed ID: 35783135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.
    Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W
    Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease.
    Scheffels JF; Fröhlich L; Kalbe E; Kessler J
    J Neurol Sci; 2020 May; 412():116735. PubMed ID: 32087430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
    Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
    PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures.
    Kim HM; Nazor C; Zabetian CP; Quinn JF; Chung KA; Hiller AL; Hu SC; Leverenz JB; Montine TJ; Edwards KL; Cholerton B
    Clin Park Relat Disord; 2019; 1():91-97. PubMed ID: 32368733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson's Disease.
    Kim JI; Sunwoo MK; Sohn YH; Lee PH; Hong JY
    J Mov Disord; 2016 Sep; 9(3):152-9. PubMed ID: 27667187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of cognitive impairment in an early stage Parkinson's disease cohort.
    Hu MT; Szewczyk-Królikowski K; Tomlinson P; Nithi K; Rolinski M; Murray C; Talbot K; Ebmeier KP; Mackay CE; Ben-Shlomo Y
    Mov Disord; 2014 Mar; 29(3):351-9. PubMed ID: 24395708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates.
    Chou KL; Lenhart A; Koeppe RA; Bohnen NI
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1076-80. PubMed ID: 25085750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease.
    Garcia-Diaz AI; Segura B; Baggio HC; Marti MJ; Valldeoriola F; Compta Y; Vendrell P; Bargallo N; Tolosa E; Junque C
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1405-10. PubMed ID: 25457818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.
    Hoops S; Nazem S; Siderowf AD; Duda JE; Xie SX; Stern MB; Weintraub D
    Neurology; 2009 Nov; 73(21):1738-45. PubMed ID: 19933974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease.
    Camargo CHF; Tolentino ES; Bronzini A; Ladeira MA; Lima R; Schultz-Pereira GL; Young-Blood MR
    Dement Neuropsychol; 2016; 10(4):344-350. PubMed ID: 29213480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.